A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)

NCT07683728 · tracked via the Priya Life Science China tracker

Sponsor

Zuojun Xu

Phase

Observational

Started

2025-09-23

Last updated

2026-07-06

Condition(s) studied

Progressive Pulmonary Fibrosis

Study summary

This is a nationwide multicenter prospective non-interventional registry study enrolling 600 Chinese patients diagnosed with PPF over a 3-year period (9-month enrollment, 2-year follow-up, and 3 months for data analysis and publication). Eligible participants must meet the PPF criteria defined by the 2022 ATS/ERS/JRS/ALAT guidelines, while patients with IPF, no baseline chest HRCT, or refusal to sign informed consent will be excluded. The primary endpoint is the absolute change in FVC (mL) at 1- and 2-year follow-ups. The core objective is to investigate real-world disease progression in Chinese PPF patients, with secondary objectives to analyze their clinical characteristics, current treatment status, and unmet clinical needs.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Diagnosis of PPF within the past year, according to the 2022 ATS/ERS/JRS/ALAT guidelines; 2. Patients who are willing to participate in the study and have signed an informed consent form. Exclusion Criteria: 1. Patients diagnosed with IPF. 2. Patients without baseline chest HRCT. 3. Patients who refuse to sign the informed consent form. 4. Patients participating in other clinical trials for medications. (Patients who have completed other trials or are in an unblinded phase after a washout period of 2 weeks are eligible for enrollment.)

Primary outcome measure(s)

Absolute change in FVC (mL) — at 1-year and 2-year follow-up
Absolute change in FVC (mL) at 1-year and 2-year follow-up.

Trial sites (1)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	China	Recruiting

Other trials for the same condition

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis Active, not recruiting

Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07683728 on ClinicalTrials.gov ↗ ← All trials in China